LA-ADTRAN
15.8.2024 14:01:35 CEST | Business Wire | Press release
Adtran today announced that PhireLink has deployed its open and intelligent fiber access technology to bring high-quality broadband to some of Louisiana’s most underserved rural communities. The deployment features Adtran’s Mosaic One software-as-a-service and its Intellifi® connected home solution to support a robust end-user experience. Using Adtran’s AI-driven platform, PhireLink is rapidly scaling a highly efficient, future-facing network capable of delivering critical public services, such as remote learning and telemedicine, and stimulating economic growth across the region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815958625/en/
Adtran’s networking technology is helping PhireLink deliver high-speed broadband to rural communities across Louisiana. (Photo: Business Wire)
“We selected Adtran for its open, scalable technology. Our new solution helps us bring dependable, high-speed broadband to more rural communities across Louisiana,” said Glen F. Post, III, CEO of PhireLink. “Working in close collaboration with Adtran’s team, we are not just constructing a network. We’re taking a crucial step towards bridging the digital divide, providing the broadband access needed to invigorate local economies and drive sustained improvements in quality of life.”
Mosaic One empowers PhireLink to enhance operational efficiency, minimize the need for on-site visits, and effectively engage with communities by utilizing materials tailored to local market needs. The end-to-end Combo PON solution also features Adtran’s scalable 10Gbit/s optical line terminal and its SDX 600 Series optical network terminals. What’s more, Adtran’s connected home solution, Intellifi®, is being harnessed in combination with Adtran’s SDG 800 Series Wi-Fi 6 gateways to provide a comprehensive in-home Wi-Fi experience. PhireLink’s customer service representatives can use the platform to resolve connectivity issues remotely, further streamlining operations and ensuring an exceptional customer experience.
“Bridging the digital divide isn’t just a case of deploying the latest and greatest hardware and software. You also need to work closely with clients to overcome challenges unique to each deployment. This is where Adtran excels. We listen to what our clients need and respond with tailored solutions that get the best out of our innovation and give subscribers a great user experience,” commented John Scherzinger, GM of Americas sales at Adtran. “Working closely with PhireLink, we’ve ensured more people in the Slidell area have access to fast and reliable fiber-based internet. But it doesn’t end there. Our Intellifi® cloud-managed Wi-Fi platform enables subscribers to gain better control, personalize and secure their Wi-Fi networks.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
About PhireLink
PhireLink is a broadband internet service provider delivering high-quality, high-speed internet across rural America. At PhireLink, we’re more than just an internet provider — we’re neighbors, dedicated to bringing the power of high-speed connectivity to every corner of the communities we serve. We're driven by one simple goal: level the playing field and ensure everyone, no matter where they live, has access to the limitless opportunities the internet provides. To learn more, visit PhireLink.com.
Published by
ADTRAN Holdings, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240815958625/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom